PALMIRA

PALBOCICLIB RECHALLENGE IN HORMONE RECEPTOR-POSITIVE/HER2-NEGATIVE ADVANCED BREAST CANCER – PALMIRA

https://clinicaltrials.gov/study/NCT03809988

HER2+ ABC

198

Spain, France, Italy, UK, Germany, Slovenia

Closing

CLINICAL TRIAL DETAILS

INTERNATIONAL, MULTICENTER, RANDOMIZED, OPEN-LABEL, PHASE II CLINICAL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF CONTINUATION OF PALBOCICLIB IN COMBINATION WITH SECOND-LINE ENDOCRINE THERAPY IN HORMONE RECEPTOR-POSITIVE/HER2-NEGATIVE ADVANCED BREAST CANCER PATIENTS WHO HAVE ACHIEVED CLINICAL BENEFIT DURING FIRST-LINE PALBOCICLIB-BASED TREATMENT. THE PRIMARY GOAL IS TO COMPARE THE EFFICACY, DEFINED AS PROGRESSION-FREE SURVIVAL (PFS), OF CONTINUATION OF PALBOCICLIB TREATMENT COMBINED WITH SECOND-LINE ENDOCRINE THERAPY (FULVESTRANT OR LETROZOLE) VERSUS ENDOCRINE THERAPY ALONE IN PRE- AND POST-MENOPAUSAL WOMEN WITH HR-POSITIVE/HER2-NEGATIVE ADVANCED BREAST CANCER (ABC). IN ADDITION, TO EXPLORE POTENTIAL MOLECULAR MARKERS OF SENSITIVITY AND/OR RESISTANCE FOR THE COMBINATION AND ENDOCRINE THERAPY ALONE.

TUMOR TYPE

PHASE

SITES

COUNTRY

STATUS

PRESS RELEASE

2023 Press Release: https://www.newswise.com/articles/medsir-study-finds-no-progression-free-survival-benefit-with-palbociclib-maintenance-after-first-line-regimen-in-hr-her2-advanced-breast-cancer-patients

SCIENTIFIC IMPACT

ASCO 2023 presentation: https://www.medsir.org/_files/ugd/39f166_4d65b7e907f0403d9806d9b16241888b.pdf | ASCO 2023 lay language summary: https://d9ec78c0-6610-4e58-b628-a2262f2019e2.usrfiles.com/ugd/d9ec78_d868fbb13daa470eab31038cc8ae55d5.pdf | PALMIRA Case Study 2023: https://www.medsir.org/_files/ugd/39f166_d6c74371b4d34903ab6103d9592e5d5b.pdf | ESMO 2019 poster: https://39f1664e-7766-40bf-9b5a-e3575d54bba6.usrfiles.com/ugd/39f166_02aba7bef9e74b10a7eca72c9fbb3719.pdf

BLOG ARTICLES RELATED

Advancing Oncology Care: MEDSIR at ASCO Annual Meeting: https://www.medsir.org/post/advancing-oncology-care-medsir-at-asco-annual-meeting | MEDSIR at ASCO 2023: https://www.medsir.org/post/news-coverage-medsir-at-asco-2023 | MEDSIR Study Finds No Progression-Free Survival Benefit with Palbociclib Maintenance After First-Line: https://www.medsir.org/post/medsir-study-finds-no-progression-free-survival-benefit-with-palbociclib-maintenance-after-first-lin | A new milestone achieved in PALMIRA Study!: https://www.medsir.org/post/a-new-milestone-achieved-in-palmira-study | PALMIRA study Poster Presentation at ESMO 2019 Congress: https://www.medsir.org/post/palmira-study-poster-presentation-at-esmo-2019-congress | First Patient In PALMIRA study: https://www.medsir.org/post/first-patient-in-palmira-study

PHERGAIN SITES

Hospital Arnau de Vilanova (Spain) | Instituto Valenciano de Oncología (IVO) (Spain) | Hospital Universitari i Politècnic La Fe (Spain) | Consorci Hospital General Universitari de València (Spain) | Hospital Provincial de Castellón (Spain) | Hospital Universitari Vall D'Hebron (Spain) | Hospital del Mar (Spain) | Instituto Oncológico Baselga - Hospital Quiron Salud Barcelona (Spain) | Institut Català d'Oncologia L'Hospitalet (ICO) (Spain) | Institut Català d'Oncologia Badalona (ICO) (Spain) | Institut Català d'Oncologia Girona (ICO) (Spain) | Consorci Hospitalari de Terrassa (Spain) | Hospital Universitari Sant Joan de Reus (Spain) | Hospital Universitario Arnau de Vilanova de Lleida (Spain) | Hospital Universitari Son Espases (Spain) | Hospital Clínico Universitario Lozano Blesa (Spain) | Hospital Universitario Miguel Servet (Spain) | Hospital Clínico San Carlos (Spain) | Hospital Universitario La Paz (Spain) | Hospital Universtitario Sanchinarro (Spain) | Hospital Universitario de Basurto (Spain) | Centro Oncológico de Galicia (Spain) | Hospital Álvaro Cunqueiro (Spain) | Hospital Universitario Virgen del Rocío (Spain) | Hospital Universitario Virgen de la Macarena (Spain) | Hospital Regional Universitario de Málaga (Hospital Carlos Haya) (Spain) | Hospital San Pedro de Alcántara (Spain) | Hopital Europeen Georges Pompidou (France) | Hôpital Tenon AP-HP (France) | Centre Paul Strauss (France) | Hôpital Jean Minjoz (France) | Centre Georges François Leclerc (France) | Hospital Center Departmental Vendée (France) | Instituto Europeo di Oncologia (Italy) | Ospedale San Raffaello (Italy) | Ospedale Civili Brescia (Italy) | Policlinico Universitario Campus Bio-medico, Roma (Italy) | Barts Cancer Institute (UK) | Beatson West of Scotland Cancer Center (UK) | Maidstone-Kent Oncology Department (UK) | Abertawe Bro Morgannwg University Local Health Board, Singleton Hospital (UK) | Royal Cornwall Hospital NHS Trust (UK) | Darent Valley Hospital by Dartford and Gravesham NHS Trust (UK) | Technical University Munich (Germany) | Klinikum Mutterhaus der Borromäerinnen Trier (Germany) | Kliniken Essen Mitte (Germany) | UKM Brustzentrum (Germany) | University Hospital Dresden-GYN (Germany) | Klinikum Ernst von Bergmann (Germany) | Universitätsklinikum Essen Frauenklinik (Germany) | AGAPLESION Markus Krankenhaus (Germany) | Onkološki Inštitut Ljubljana (Slovenia) | Univerzitetni klinicni center Maribor Oddelek za onkologijo (Slovenia)

Dr. Cortes and Dr. Llombart PHERain interview

Beyond Chemotherapy

Dr. Vanes Quiroga

Dr. Sofia Braga

Dr. Silvi Antolín

Dr. Escrivá de Romaní

Dr. Philipp Aftimos

Dr. Manuel Ruiz

Prof. Daniele Generali PHEGain interview

Dr. Jacques Medioni

Dr. Dunca Wheatley